To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1920 | Ehi2119 |
Potent and bio-stable inhibitor of the chicken sEH (chxEH)
More description
|
|
| DCC1919 | Ehi1471 |
Potent and bio-stable inhibitor of the chicken sEH (chxEH)
More description
|
|
| DCC1918 | Eh-201 |
Arginase Inhibitor, activating EPO-mediated mitochondrial function and haemoglobin expression, stimulating melanogenesis by MAP kinase activation and tyrosinase upregulation
More description
|
|
| DCC1917 | Egonol |
Antibacterial agent
More description
|
|
| DCC1916 | Egis-8332 |
Selective, non-competitive AMPA receptor antagonist, improving motor co-ordination
More description
|
|
| DCC1915 | Egis-11150 |
Potent inhibitor of adrenergic alpha1, alpha2c, 5-HT2a, 5HT7 receptors; Relatively selective blocker of adrenergic alpha2c over adrenergic alpha2a receptors.
More description
|
|
| DCC1914 | Egfr-in-557 |
Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis
More description
|
|
| DCC1913 | Egfr-in-542 |
Novel EGFR inhibitor, significantly reducing myocardial inflammation, fibrosis, apoptosis, and dysfunction, showing promises to the treatment on obesity-induced cardiac complications
More description
|
|
| DCC1912 | Egfr-in-451 |
Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis
More description
|
|
| DCC1911 | Egfr T790m Inhibitor 6a |
Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer
More description
|
|
| DCC1910 | Efrotomycin |
Antibiotic, inhibiting bacterial protein synthesis
More description
|
|
| DCC1909 | Efrapeptin F |
Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo
More description
|
|
| DCC1908 | Efonidipine |
Calcium channel blocker, blocking both T-type and L-type calcium channels
More description
|
|
| DCC1907 | Efatutazone |
Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity
More description
|
|
| DCC1906 | Eef2k-in-21i |
Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways
More description
|
|
| DCC1905 | Edoxaban Isomer |
An impurity of Edoxaban, a novel inhibitor of factor Xa
More description
|
|
| DCC1904 | Ecraprost |
Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders
More description
|
|
| DCC1903 | Echinoside A |
Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle
More description
|
|
| DCC1902 | Ecdsbb-in-9 |
Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria
More description
|
|
| DCC1901 | Ecdsbb-in-12 |
Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme
More description
|
|
| DCC1900 | Ebv Activator C60 |
Novel EBV activator, well-performing EBV lytic cycle inducer
More description
|
|
| DCC1899 | Ebselen Oxide |
Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis
More description
|
|
| DCC1898 | Ebov-in-c31 |
Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties
More description
|
|
| DCC1897 | Ebopiprant |
Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist
More description
|
|
| DCC1896 | Ebmi-13b |
Highly potent and selective activator of isozymes CA-VA and CA-VII
More description
|
|
| DCC1895 | Ebi-13a |
Highly potent and selective activator of isozymes CA-VA and CA-VII
More description
|
|
| DCC1894 | Ea-b3a |
Novel degrader of GST-α and GST-α-EGFP fusion proteins as well as endogenous GST-π in cells and lysates
More description
|
|
| DCC1893 | E-5842 Citrate |
Sigma1 receptor ligand and potential atypical antipsychotic
More description
|
|
| DCC1892 | E3-ligase Degrader 10 |
Novel XIAP BIR2 domain-binding degrader of E3 ubiquitin ligases
More description
|
|
| DCC1891 | E235-1756 |
Potent Activator of P53-Independent Cellular Senescence
More description
|
|